| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 48,534 | 53,407 | ||
| Short-term investments | 88,609 | 54,972 | ||
| Accounts receivable, net | 45,925 | 39,907 | ||
| Inventories | 13,303 | 10,423 | ||
| Prepaid and other current assets | 18,556 | 16,684 | ||
| Total current assets | 214,927 | 175,393 | ||
| Property and equipment, net | 54 | 57 | ||
| Intangible assets, net | 25,336 | 25,924 | ||
| Operating lease right-of-use asset | 1,050 | 1,178 | ||
| Other assets | 1,167 | 4,184 | ||
| Total assets | 242,534 | 206,736 | ||
| Accounts payable | 3,846 | 7,290 | ||
| Accrued compensation | 10,065 | 7,897 | ||
| Accrued research and development | 4,816 | 4,121 | ||
| Acquisition-related liabilities | 5,000 | 5,000 | ||
| Revenue reserves and refund liability | 30,020 | 29,502 | ||
| Loans payable, net, current portion | 29,761 | 22,361 | ||
| Other accrued liabilities | 8,943 | 8,593 | ||
| Deferred revenue | 1,355 | 1,355 | ||
| Lease liabilities, current portion | 594 | 517 | ||
| Total current liabilities | 94,400 | 86,636 | ||
| Long-term portion of lease liabilities | 556 | 714 | ||
| Long-term portion of loans payable, net | 29,969 | 37,452 | ||
| Total liabilities | 124,925 | 124,802 | ||
| Common stock | 18 | 18 | ||
| Additional paid-in capital | 1,408,601 | 1,400,916 | ||
| Accumulated other comprehensive income | 96 | 6 | ||
| Accumulated deficit | -1,291,106 | -1,319,006 | ||
| Total stockholders' equity | 117,609 | 81,934 | ||
| Total liabilities and stockholders' equity | 242,534 | 206,736 | ||
RIGEL PHARMACEUTICALS INC (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL)